CClinicalTrials.gg
CompletedNCT03637894Updated Aug 20, 2018

Immunity Modification of Full Term Infants According to the Type of Feeding and Mode of Delivery

An interventional study of Feeding infants with fermented formula milk and Feeding infants with standard formula milk in Innate Immunity, Newborns and Nutrition, sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. Completed at 1 site in Italy. Open to participants aged 1 Day to 7 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-20.

Sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 2 years 4 months after the study started (first participant enrolled Aug 2015, registered Jan 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
1 Day to 7 Days
Sex
All
01

Study summary

This is a single-center, double-blind, randomized controlled trial, with parallel groups and reference group. The aim of the study was to investigate whether feed a fermented formula milk leads to an increase of anti-microbial peptides such as catelecidine, alpha and beta defensins and secretory-IgA, compared to feed a standard formula (Plasmon Primigiorni), according to mode of delivery. Breastfed infants were the reference group.

Read the detailed description

The microbiota plays an important role in modulating the development of the immune system, making decisive the interrelation that between nutrition, microbiota and immune cells to modulate long-term health outcomes.

The type of feeding, especially breastfeeding, and the type of delivery are factors that can contribute to the development of the microbiota. Specifically, the exclusive breastfeeding promotes the development of bifidobacteria that promotes protection against potential infections and the development of the immune system.

In recent years it was improved the biological effects of formula milk, that represent the substitutes of breast milk when this is not available or if there are contraindications to breastfeeding. Functional foods derived from fermentation of cow's milk with probiotic strains have been proposed for the prevention of infectious diseases of the child. Recently, in a monocentric double-blind prospective study, the efficacy of fermented cow's milk with Lactobacillus paracasei CBA L74 was evaluated in the prevention of common winter infections in children aged between 12 and 48 months. In this study, children treated with fermented milk had a lower incidence of respiratory and gastrointestinal tract infections compared to the control group. This effect was associated with a significant stimulation of innate immunity (α- and β-defensin, LL-37) and acquired (secretory IgA) and to a modulation of composition and function of the intestinal microbiota characterized by a significant increase in strains producing butyric acid (Firmicutes phyla). The nutritional intervention was very well accepted by the children and no adverse events were observed.

Primary objectives of this study were:

To evaluate whether the feeding with a fermented formulated milk determines an increase in anti-microbial peptides such as catelecidine, alpha and beta defensin and secretory IgA compared to the feed with the standard formula (Plasmon Primigiorni), with reference to the mother's milk.

Secondary objective:

  • Value the tolerance in the two groups of infants fed with the two formulas in the study, with reference to the group of infants fed with breast milk.
  • Value the modifications of the intestinal microbiota in the two groups of infants fed with the two formulas in the study, with reference to the group of infants fed with breast milk.

Study design: Single-center, randomized, double-blind, parallel group study with reference group.

Methods:

  • Evaluation of the anthropometric parameters (weight, length and cranial circumference)
  • Evaluation of body composition by plethysmography
  • Evaluation of the gastrointestinal tolerance of fermented formulated milk by means of data collection and diary delivery to the parents of the participants
  • Evaluation of the safety of fermented formulated milk by recording adverse events
  • Determination of faecal samples of antimicrobial peptides (defensins, catelecidines), IgA, microbiota and metabolome.

Infants will be enrolled at birth (within 7 days of life) upon acquisition of the informed consent of both parents.

At the time of enrollment, newborns who take breast milk due to the absence of breast milk will be randomized to receive up to the third month of age or a fermented formulated milk or a standard formula (Plasmon First Days).

Enrollment will be carried out by promoting and supporting breastfeeding and, in the event of exclusive breastfeeding forecasts for at least the first 3 months of age, newborns will be included in the study as a control group.

There are 3 medical visits to enrollment (V0), the first (V1) and the third month of life (V2).

During the visits the anthropometric parameters, the body composition, and the gastroenteric tolerance will be evaluated. A stool sample will also be collected at the three points of the life study in order to determine the anti-microbial peptides (catelecidine, alpha and beta defensin) and the secretory IgA, and perform the analysis of the microbiota and the metabolome.

Statistical analysis:

The sample size was determined to identify between the two groups of infants, the one that received the fermented formulated milk and the one that received standard formulated milk (Plasmon Primigiorni), a difference in the content of faecal α-defensins on samples of feces. Considering the results of the effect of a treatment with milk fermented with L. paracasei CBA L74 on fecal α-defensins in children attending preschool centers mean value (DS) vs placebo [4.8 (4.2) vs 1 (0.6), respectively] we calculated that 12 newborns are needed per group with a power of 84% and an alpha of 0.05. Assuming a 30% drop-out rate, at least 16 newborns per group must be recruited.

Criteria for the evaluation of variables The descriptive analyzes will be performed by calculating mean, median and standard deviations for the continuous variables and expressing the distribution of the frequencies for the discrete variables. The main analysis will resort to tests for independent samples, Student or Mann-Whitney tests according to the distribution of the outcome variables. To jointly analyze the trend in time from V0 to V2 of the outcome variables in the two groups, the one that received the fermented formulated milk and the one that received the standard formula, based on the type of delivery (spontaneous or cesarean) will be used regression models for repeated measurements (random effects models or GEE models).

02

Conditions studied

  • Innate Immunity
  • Newborns
  • Nutrition
  • Microbiota

Keywords

  • Newborns
  • Fermented milk
  • Innate immunity
03

In context

Lead sponsor

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico is the lead sponsor of 214 studies on the registry; 71 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 7 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Full term healthy infants
  • Gestational age from 37 to 41 weeks
  • Weight appropriate for gestational age (from 10th to 90th centile according to World Health Organization chart)
  • Human milk not available or not possible

Exclusion criteria

Exclusion criteria:

  • Weight small for gestational age (\< 10th centile) or large for gestational age (> 90th centile) according to World Health Organization chart
  • Congenital abnormalities, chromosomal, hearth, gastrointestinal, respiratory, neurological or metabolic disease.
  • Perinatal infections
  • Positive familiarity for milk proteins allergies
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
96 participants (actual)

Study arms

  • Active comparator
    Infants born by CS-fed fermented formula

    Feeding infants with fermented formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life

    Dietary Supplement: Feeding infants with fermented formula milk

  • Placebo comparator
    Infants born by CS-fed standard formula

    Feeding infants with standard formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life

    Other: Feeding infants with standard formula milk

  • Other
    Infants born by CS-breastfed

    Infants born by cesarean section fed with mother milk during were the reference group for all infants born by cesarean section. The breastfeeding infants were the reference group

    Other: Breastfeeding infants

  • Active comparator
    Infants born by ED-fed fermented formula

    Feeding infants with fermented formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life

    Dietary Supplement: Feeding infants with fermented formula milk

  • Placebo comparator
    Infants born by ED-fed standard formula

    Feeding infants with standard formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life

    Other: Feeding infants with standard formula milk

  • Other
    Infants born by ED-breastfed

    Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life. The breastfeeding infants were the reference group.

    Other: Breastfeeding infants

Interventions

  • Dietary supplementFeeding infants with fermented formula milk

    Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.

  • OtherFeeding infants with standard formula milk

    Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.

  • OtherBreastfeeding infants

    Reference group

06

What researchers measure

Primary outcomes

  1. Change from baseline Innate immunity at 30 days of life and at 90 days of life.

    Fecal dosage of catelecidines, alfa and beta defensins and sIgA

    Time frame: 0-7 days of life, at 30 days of life and at 90 days of life.

Secondary outcomes

  1. Gastrointestinal tolerance

    Gastrointestinal tolerance was evaluated by the use of a daily diary computed by the parents to record vomiting/gaseous colics/stool frequency.

    Time frame: 0-7 days of life, at 30 days of life and at 90 days of life.

  2. Weight

    weight (g)

    Time frame: 0-7 days of life, at 30 days of life and at 90 days of life.

  3. Body composition

    Body composition assessment in term of fat mass and fat free mass by air displacement

    Time frame: 0-7 days of life and at 90 days of life.

  4. Anthropometry

    length and head circumference (cm)

    Time frame: 0-7 days of life, at 30 days of life and at 90 days of life.

  5. Microbiota

    gut microbiota assessment

    Time frame: 0-7 days of life and at 90 days of life.

  6. Metabolomics

    stool metabolomic analysis

    Time frame: 0-7 days of life and at 90 days of life.

07

Study locations

1 site
  • Fondazione Ca' Granda Ospedale Maggiore Policlinico
    Milan, 20122, Italy
08

References and documents

Publications

  • Nocerino R, Paparo L, Terrin G, Pezzella V, Amoroso A, Cosenza L, Cecere G, De Marco G, Micillo M, Albano F, Nugnes R, Ferri P, Ciccarelli G, Giaccio G, Spadaro R, Maddalena Y, Berni Canani F, Berni Canani R. Cow's milk and rice fermented with Lactobacillus paracasei CBA L74 prevent infectious diseases in children: A randomized controlled trial. Clin Nutr. 2017 Feb;36(1):118-125. doi: 10.1016/j.clnu.2015.12.004. Epub 2015 Dec 17. PubMed 26732025 ↗
  • Zagato E, Mileti E, Massimiliano L, Fasano F, Budelli A, Penna G, Rescigno M. Lactobacillus paracasei CBA L74 metabolic products and fermented milk for infant formula have anti-inflammatory activity on dendritic cells in vitro and protective effects against colitis and an enteric pathogen in vivo. PLoS One. 2014 Feb 10;9(2):e87615. doi: 10.1371/journal.pone.0087615. eCollection 2014. PubMed 24520333 ↗
  • Thibault H, Aubert-Jacquin C, Goulet O. Effects of long-term consumption of a fermented infant formula (with Bifidobacterium breve c50 and Streptococcus thermophilus 065) on acute diarrhea in healthy infants. J Pediatr Gastroenterol Nutr. 2004 Aug;39(2):147-52. doi: 10.1097/00005176-200408000-00004. PubMed 15269618 ↗
  • Indrio F, Ladisa G, Mautone A, Montagna O. Effect of a fermented formula on thymus size and stool pH in healthy term infants. Pediatr Res. 2007 Jul;62(1):98-100. doi: 10.1203/pdr.0b013e31806772d3. PubMed 17515847 ↗
  • Roggero P, Liotto N, Pozzi C, Braga D, Troisi J, Menis C, Gianni ML, Berni Canani R, Paparo L, Nocerino R, Budelli A, Mosca F, Rescigno M. Analysis of immune, microbiota and metabolome maturation in infants in a clinical trial of Lactobacillus paracasei CBA L74-fermented formula. Nat Commun. 2020 Jun 1;11(1):2703. doi: 10.1038/s41467-020-16582-1. PubMed 32483147 ↗

Individual participant data

Plan to share: No — The individual participant data will not shared with other researchers.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03637894
Lead sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Collaborators
Heinz Italia SpA
Responsible party
Sponsor
First posted
Aug 20, 2018
Start date
Aug 26, 2015
Primary completion
Jun 21, 2017
Completion
Jun 21, 2017
Last update
Aug 20, 2018

Study contacts

Fabio Mosca, Prof
principal investigator · NICU. Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Milan, Italy, 20122

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion